The obvious improvement of skin lesions in patients with psoriasis type 2 diabetes mellitus after liraglutide treatment may be related to inhibition of the expression of inflammatory factors such as IL-23, IL-17, and TNF-α (103). This evidence concerns the gene IL17A and type 2 diabetes mellitus.